Our current study explores the involvement of MIF in the development of obesity, insulin resistance, and hyperlipidemia caused by other AAPs, including CLZ, APZ, RIS, and QTP, which are commonly prescribed in clinical settings. Here, MIF is linked to hyperlipidemia.